Literature DB >> 10857386

Serotonin, dopamine and norepinephrine transporters in the central nervous system and their inhibitors.

B Olivier1, W Soudijn, I van Wijngaarden.   

Abstract

An overview is presented on progress made in the research on neuronal transporters of serotonin, dopamine and norepinephrine in the central nervous system. Tools developed by molecular biology, such as expression of cloned transporters, their mutants and chimera in non-neuronal cells offered the opportunity to study the putative domains for binding of substrates and uptake inhibitors and discover factors in the regulation of the transporter function. The study of the distribution of monoamine transporters in human brain became possible by the development of selective radiolabelled transport inhibitors. The relationships between the chemical structure of the uptake inhibitors and the affinity for the monoamine transporters is reported, and the (potential) therapeutic applications of the compounds are discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10857386     DOI: 10.1007/978-3-0348-8391-7_3

Source DB:  PubMed          Journal:  Prog Drug Res        ISSN: 0071-786X


  14 in total

Review 1.  Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6.

Authors:  Nian-Hang Chen; Maarten E A Reith; Michael W Quick
Journal:  Pflugers Arch       Date:  2003-04-29       Impact factor: 3.657

2.  Norepinephrine transporter inhibitors and their therapeutic potential.

Authors:  Jia Zhou
Journal:  Drugs Future       Date:  2004-12       Impact factor: 0.148

3.  The Role of the Serotonergic System in REM Sleep Behavior Disorder.

Authors:  Dario Arnaldi; Francesco Famà; Fabrizio De Carli; Silvia Morbelli; Michela Ferrara; Agnese Picco; Jennifer Accardo; Alberto Primavera; Gianmario Sambuceti; Flavio Nobili
Journal:  Sleep       Date:  2015-09-01       Impact factor: 5.849

Review 4.  Advancing Drug Discovery and Development Using Molecular Imaging (ADDMI): an Interest Group of the World Molecular Imaging Society and an Inaugural Session on Positron Emission Tomography (PET).

Authors:  Shil Patel; Karl Schmidt; Jacob Hesterman; Jack Hoppin
Journal:  Mol Imaging Biol       Date:  2017-06       Impact factor: 3.488

5.  Is correction for age necessary in neuroimaging studies of the central serotonin transporter?

Authors:  Swen Hesse; Henryk Barthel; Toshiya Murai; Ulrich Müller; Dominic Müller; Anita Seese; Regine Kluge; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01-16       Impact factor: 9.236

6.  Interaction of the human plasma membrane monoamine transporter (hPMAT) with antidepressants and antipsychotics.

Authors:  Britta Haenisch; Heinz Bönisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-10       Impact factor: 3.000

7.  Three-dimensional quantitative structure-activity relationship (3D QSAR) and pharmacophore elucidation of tetrahydropyran derivatives as serotonin and norepinephrine transporter inhibitors.

Authors:  Prashant S Kharkar; Maarten E A Reith; Aloke K Dutta
Journal:  J Comput Aided Mol Des       Date:  2007-12-04       Impact factor: 3.686

8.  Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter.

Authors:  Nicholas V Cozzi; Anupama Gopalakrishnan; Lyndsey L Anderson; Joel T Feih; Alexander T Shulgin; Paul F Daley; Arnold E Ruoho
Journal:  J Neural Transm (Vienna)       Date:  2009-09-12       Impact factor: 3.575

9.  Calcium/calmodulin-dependent kinase II regulates the interaction between the serotonin transporter and syntaxin 1A.

Authors:  Marcia A Ciccone; Miranda Timmons; Anthony Phillips; Michael W Quick
Journal:  Neuropharmacology       Date:  2008-06-18       Impact factor: 5.250

10.  Monoamine transporter availability in Parkinson's disease patients with or without depression.

Authors:  Swen Hesse; Philipp M Meyer; Karl Strecker; Henryk Barthel; Florian Wegner; Christian Oehlwein; Ioannis Ugo Isaias; Johannes Schwarz; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-27       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.